Expand BCAX Menu
BCAX MENU

BCAX Latest Press Releases

-- May 21, 2026 --

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF- Inhibition in 1L R/M HPV-Negative HNSCC Globe Newswire 5:00 PM

-- May 13, 2026 --

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM

-- May 11, 2026 --

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 7:30 AM

-- May 4, 2026 --

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET Globe Newswire 8:30 AM

-- April 3, 2026 --

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM

-- March 30, 2026 --

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 7:30 AM

-- March 23, 2026 --

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET Globe Newswire 8:30 AM

-- March 4, 2026 --

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM

-- February 26, 2026 --

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Globe Newswire 4:01 PM

-- February 24, 2026 --

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 11:13 PM
Bicara Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- February 23, 2026 --

Bicara Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- February 19, 2026 --

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen Globe Newswire 4:30 PM

-- February 5, 2026 --

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes